Bank of New York Mellon Corp purchased a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 36,913 shares of the company's stock, valued at approximately $607,000. Bank of New York Mellon Corp owned approximately 0.07% of Upstream Bio as of its most recent filing with the Securities & Exchange Commission.
Separately, Moody Aldrich Partners LLC purchased a new stake in shares of Upstream Bio in the 4th quarter valued at about $1,229,000.
Upstream Bio Stock Performance
NASDAQ UPB traded up $0.06 during trading on Friday, reaching $6.87. The company's stock had a trading volume of 138,106 shares, compared to its average volume of 327,883. Upstream Bio, Inc. has a twelve month low of $6.63 and a twelve month high of $29.46. The business's fifty day moving average is $8.63.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Further Reading
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
